CYP3A4 and CYP3A5
Also known as: 3A4/3A5
Use
Use to assess genetic risk of abnormal drug metabolism for CYP3A4 and/or CYP3A5 substrates. This test may aid in drug selection and dose planning for drugs metabolized by CYP3A4 and/or CYP3A5. Variants in these genes may influence pharmacokinetics of CYP3A substrates, predicting or explaining nonstandard dose requirements, therapeutic failure, or adverse reactions.
Special Instructions
Counseling and informed consent are recommended for genetic testing. Informed consent for genetic testing is required for NY patients and linked above. New York clients must include informed consent with submission.
Limitations
Only the targeted CYP3A4 and CYP3A5 variants will be detected by this panel, and assumptions about phase and content are made to assign alleles. Diagnostic errors can occur due to rare sequence variations. Genetic and nongenetic factors not detected by this test may influence therapeutic failure or adverse reactions with CYP3A substrates. This result does not replace the need for therapeutic drug or clinical monitoring.
New York Approved
Methodology
PCR-based (PCR)
Biomarkers
LOINC Codes
- 31208-2
- 81139-8
- 81140-6
- 50398-7
- 79717-5
- 11526-1
Result Turnaround Time
5-10 days
Related Documents
For more information, please review the documents below
Specimen
Whole Blood
Volume
3 mL
Minimum Volume
1 mL
Container
Lavender (EDTA), pink (K2EDTA), or yellow (ACD solution A or B)
Storage Instructions
Preferred transport temp: Refrigerated.
Causes for Rejection
Plasma or serum. Specimens collected in sodium heparin or lithium heparin. Frozen specimens in glass collection tubes.
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 3 days |
| Refrigerated | 1 week |
| Frozen | 1 month |